**Key Facts**
- MDMA-assisted therapy (MDMA-AT) significantly reduces symptoms of post-traumatic stress disorder (PTSD) compared to placebo in controlled clinical trials.
- MDMA-AT is generally well-tolerated with few severe adverse events reported.
- Long-term follow-up shows sustained benefits, with many participants no longer meeting PTSD criteria after 12 months.
- MDMA remains a Schedule I controlled substance, limiting its current medical availability and acceptance.
- Most research focuses on severe PTSD; effectiveness for other conditions or broader populations is not yet established (clinicaltrials.gov; MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study - Pu…; 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress d…).
**Source-Based Paraphrases**
- A phase 3 randomized, double-blind study demonstrated a significant reduction in PTSD symptoms with MDMA-AT versus placebo, with a large effect size and good safety profile (MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study - Pu…).
- Long-term data from a phase 2 trial indicate that the therapeutic effects of MDMA-assisted psychotherapy can persist for at least one year post-treatment (3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress d…).
- Ongoing clinical trials are exploring MDMA-assisted therapy for other disorders such as obsessive-compulsive disorder, but evidence remains preliminary (MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)).
**Summary**
MDMA-assisted therapy has emerged as a promising treatment for PTSD, showing significant symptom reduction and sustained benefits in rigorous clinical trials. Its generally favorable safety profile under professional supervision supports its therapeutic potential. However, regulatory restrictions and limited research beyond PTSD mean MDMA-AT is not yet widely available or established for other mental health conditions. Continued research is essential to clarify its broader applicability and long-term safety.
**Verified Sources**
- clinicaltrials.gov
- MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study - PubMed
- 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled tria…
- jamanetwork.com
Source verification: Verified | Checked direct sources: 5 | Independent domains: 5
AI assessment: The article is strongly supported by multiple high-quality, peer-reviewed clinical trials and authoritative clinical trial registries demonstrating MDMA-assisted therapy's efficacy and safety for PTSD treatment. It accurately reflects the current regulatory status and the need for further research on broader applications and long-term effects. The sources are authoritative and relevant, with no major factual errors or invented details detected. Some minor viewpoint variance exists due to regulatory caution and ongoing research, but the article fairly presents these perspectives.
Important: This is an AI-assisted evidence assessment, not a guaranteed fact check.
Article link: https://mytrilens.com/article.php?slug=is-mdma-a-good-form-of-therapy
Validation build: 2026-07-14a-username-email-cooldown
Comment to article author